2023 World Conference on Lung Cancer (Posters)-EP02.01. Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma

EP02.01. Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the therapeutic potential of combining a KRAS G12C inhibitor and an mTOR inhibitor in lung adenocarcinoma and squamous cell carcinoma. The researchers assessed the frequency of KRAS G12C mutation in resected lung adenocarcinoma and squamous cell carcinoma cases and evaluated the combination effect of KRAS and mTOR inhibitors in cell lines.<br /><br />The results showed that the frequency of KRAS G12C mutation was similar in both adenocarcinoma and squamous cell carcinoma cases. The combination of different KRAS inhibitors (AMG-510, MRTX849, and ARS-1620) with the mTOR inhibitor Everolimus demonstrated synergistic effects in both adenocarcinoma and squamous cell carcinoma cell lines. The growth of the cells was suppressed in a dose-dependent manner, regardless of the specific KRAS inhibitor used.<br /><br />These findings suggest that the KRAS G12C mutation may be a targetable somatic variant in squamous cell carcinoma, similar to its role in adenocarcinoma. The combination strategy of using a KRAS inhibitor and an mTOR inhibitor shows promise for treating these two major types of lung cancer.<br /><br />The study highlights the importance of understanding the molecular therapeutic targets in tumor biology. By targeting specific genetic mutations, such as KRAS G12C, and using combination therapies, researchers may improve treatment outcomes for lung adenocarcinoma and squamous cell carcinoma.

Asset Subtitle

Masaoki Ito

Meta Tag

Speaker Masaoki Ito

Topic Tumor Biology: Preclinical Biology - Molecular Therapeutic Targets

Keywords

therapeutic potential

KRAS G12C inhibitor

mTOR inhibitor

lung adenocarcinoma

squamous cell carcinoma

KRAS G12C mutation

combination effect

KRAS inhibitors

Everolimus

targetable somatic variant